Research showed that patients who lose weight on GLP-1 agonists frequently experience muscle mass loss. Obesity experts share ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Expanding volumes of data point to mechanisms beyond weight loss and blood sugar control that contribute to cardiovascular ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...

The GLP-1 drugs are "truly causing a lot of disruption for the surgeons and for the programs, and for patients," Thomas Tsai, MD, a bariatric surgeon at Brigham and Women's Hospital in Boston, told ...

Following billionaire investors isn't as difficult as you might imagine thanks to quarterly reporting required by the ...

For comparison, with subcutaneous dosing ... Further, whether a small-molecule inhibitor GLP-1 agonist can outperform a dual GLP-1/GIP agonist is speculative. Indeed, Lilly reported (as discussed ...

It's been an excellent year for Viking Therapeutics ( VKTX 4.30%), a mid-cap biotech company. Thanks to impressive mid-stage ...

GLP-1 agonists are used to treat diabetes and chronic ... Lilly is the maker of GLP-1 treatments Mounjaro and Zepbound. For comparison’s sake, Mounjaro is essentially Lilly's answer to Ozempic ...

NXE-0048149 is under clinical development by Nxera Pharma and currently in Phase I for Psychosis. According to GlobalData, Phase I drugs for Psychosis have a 59% phase transition success rate (PTSR) ...